Nano-propolis

PreclinicalSmall molecule

CCairo University

Nano-propolis is one of 6 small molecule programs targeting IgAN. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IganUnknown status

IganPreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Igan

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Nubeqa

Bayer

Phase 2

1 3

TRUTAKNA

VVera Therapeutics, Inc.

Phase 2

1 4

ADX-038

AADARx Pharmaceuticals, Inc.

Phase 2

1 5

Propolis

IIndonesia University

Preclinical

1 6

Nano-propolis

CCairo University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

IgAN1 trial

Using Three Different Final Irrigants and Showing Their Effects on the Success of Revascularization

Unknown status·—·N/A·NCT03591172·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nano-propolis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nano-propolis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nano-propolis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCairo University

Nano-propolis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

IgAN1 trial

References

Drug Info

Quick Facts

Related News